Switch theme
Sign up to access all valuation multiples
Theraclion is a France-based company specializing in high-tech therapeutic ultrasound equipment. The product, Echopulse, helps in the treatment of breast fibroadenomas and benign thyroid nodules.
2004
29
LTM Revenue n/a
LTM EBITDA n/a
$2.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Theraclion has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Theraclion achieved revenue of $2.0M and an EBITDA of -$2.2M.
Theraclion expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Theraclion valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.0M | n/a | XXX | XXX | XXX |
| Gross Profit | -$1.5M | -$4.2M | XXX | XXX | XXX |
| Gross Margin | -77% | NaN% | XXX | XXX | XXX |
| EBITDA | -$2.2M | n/a | XXX | XXX | XXX |
| EBITDA Margin | -113% | NaN% | XXX | XXX | XXX |
| Net Profit | -$4.0M | -$5.3M | XXX | XXX | XXX |
| Net Margin | -206% | NaN% | XXX | XXX | XXX |
| Net Debt | $0.5M | $23K | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Theraclion's stock price is EUR 0 (or $0).
Theraclion has current market cap of EUR 6.6M (or $7.1M), and EV of EUR 2.3M (or $2.5M).
See Theraclion trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.5M | $7.1M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Theraclion has market cap of $7.1M and EV of $2.5M.
Theraclion's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Theraclion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Theraclion and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.5M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpTheraclion's NTM/LTM revenue growth is n/a
Theraclion's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Theraclion's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Theraclion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Theraclion and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 113% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Theraclion acquired XXX companies to date.
Last acquisition by Theraclion was XXXXXXXX, XXXXX XXXXX XXXXXX . Theraclion acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Theraclion founded? | Theraclion was founded in 2004. |
| Where is Theraclion headquartered? | Theraclion is headquartered in France. |
| How many employees does Theraclion have? | As of today, Theraclion has 29 employees. |
| Is Theraclion publicy listed? | Yes, Theraclion is a public company listed on PAR. |
| What is the stock symbol of Theraclion? | Theraclion trades under ALTHE ticker. |
| When did Theraclion go public? | Theraclion went public in 2014. |
| Who are competitors of Theraclion? | Similar companies to Theraclion include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Theraclion? | Theraclion's current market cap is $7.1M |
| Is Theraclion profitable? | Yes, Theraclion is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
